clinician
need
know
antivir
drug
viral
resist
richard
l
hodinka
phd
last
decad
signific
advanc
made
develop
use
antivir
agent
success
treatment
number
viral
expand
array
antivir
drug
current
avail
manag
infect
caus
herp
simplex
viru
type
cytomegaloviru
cmv
varicellazost
viru
vzv
influenza
viru
respiratori
syncyti
viru
rsv
human
immunodefici
viru
type
papillomavirus
hepat
b
c
virus
increas
number
use
antivir
agent
howev
led
emerg
drugresist
virus
particularli
immunocompromis
patient
acquir
immunodefici
syndrom
aid
hematolog
malign
undergon
organ
transplant
comprehens
review
specif
virus
see
refer
clinic
situat
favor
develop
resist
includ
longterm
suppress
therapi
recurr
intermitt
therapi
use
less
optimum
dose
antivir
agent
gener
emerg
isol
drugresist
virus
associ
therapeut
use
antivir
agent
seem
caus
prophylact
treatment
patient
fail
respond
appropri
therapi
addit
antivir
agent
produc
also
becom
import
diagnost
virolog
laboratori
provid
rapid
practic
antivir
suscept
test
assist
physician
defin
drug
resist
choos
appropri
altern
therapi
review
describ
major
antivir
agent
mechan
action
develop
drug
resist
follow
antivir
therapi
brief
overview
avail
phenotyp
genotyp
suscept
assay
detect
antivir
resist
also
discuss
human
herpesvirus
worldwid
distribut
frequent
caus
infect
immunocompet
immunocompromis
host
number
sever
lifethreaten
condit
caus
virus
signific
includ
local
oral
genit
dermal
infect
chickenpox
infecti
mononucleosi
enceph
posttranspl
lymphoprolif
disord
roseola
infantum
number
antivir
agent
licens
clinic
use
treatment
prophylaxi
herpesviru
infect
tabl
nucleosid
analog
requir
convers
mono
di
triphosph
form
either
cellular
kinas
viral
kinas
select
inhibit
replic
herpesvirus
class
includ
vidarabin
acyclovir
valacyclovir
famciclovir
ganciclovir
cidofovir
idoxuridin
trifluridin
second
class
antivir
drug
action
herpesvirus
repres
recent
develop
pyrophosph
analog
foscarnet
vidarabin
adenin
arabinosid
araa
viraa
adenosin
nucleosid
analog
vitro
activ
vzv
cmv
ebv
vaccinia
viru
hepat
b
viru
vivo
activ
limit
vzv
drug
licens
ophthalm
intraven
use
unit
state
although
mechan
action
vidarabin
unclear
drug
phosphoryl
cellular
kinas
triphosph
form
prevent
viral
dna
synthesi
inhibit
viral
dna
polymeras
vidarabin
efficaci
treatment
herp
enceph
neonat
hsv
infect
herp
kerat
mucocutan
hsv
infect
zoster
immunocompromis
host
drug
easi
use
howev
toxic
poor
solubl
water
rapid
deamin
vivo
less
activ
compound
arahypoxanthin
vidarabin
seldom
use
larg
replac
acyclovir
resist
vidarabin
identifi
clinic
set
although
drugresist
isol
induc
laboratori
caus
alter
viral
dna
vidarabin
vitro
activ
acyclovirresist
hsv
vzv
isol
drug
proven
use
treatment
isol
hivinfect
acyclovir
guanin
acycloguanosin
zovirax
guanosin
analog
good
vitro
activ
vzv
limit
activ
cmv
ebv
human
use
clinic
treatment
hsv
vzv
infect
acyclovir
accumul
cell
infect
herpesvirus
phosphoryl
viralspecif
thymidin
kinas
monophosph
form
phosphoryl
diphosph
activ
triphosph
form
cellular
enzym
acyclovir
triphosph
inhibit
viral
dna
polymeras
act
immedi
dna
chain
termin
acyclovir
efficaci
treatment
primari
recurr
hsv
vzv
infect
hsv
enceph
neonat
herp
manag
mucocutan
hsv
infect
resist
acyclovir
result
mutat
gene
encod
viral
thymidin
kinas
tk
viral
dna
mutat
gene
tk
result
viral
isol
either
defici
tk
alter
product
tka
viral
thymidin
kinas
ativ
viral
isol
tkphenotyp
caus
decreas
lack
acyclovir
phosphoryl
wherea
tka
strain
result
alter
substrat
bind
properti
acyclovir
valacyclovir
lvalin
methoxi
ethyl
ester
valtrex
lvalyl
ester
acyclovir
recent
licens
treatment
recurr
genit
hsv
infect
herp
zoster
immunocompet
adult
drug
rapidli
extens
convert
acyclovir
oral
administr
result
fold
increas
bioavail
acyclovir
observ
oral
dose
acyclovir
date
clinic
resist
valacyclovir
compar
suscept
acyclovirresist
clinic
isol
valacyclovir
acyclovir
report
expect
mechan
viral
resist
valacyclovir
howev
like
acyclovir
famciclovir
ethyl
diacet
famvir
synthet
guanin
deriv
oral
administ
prodrug
antivir
compound
approv
use
adult
treatment
recurr
genit
hsv
herp
zoster
rapidli
extens
absorb
follow
oral
administr
convert
activ
triphosph
form
penciclovir
mechan
similar
acyclovir
like
acyclovir
penciclovir
good
vitro
activ
hsv
vzv
limit
activ
ebv
cmv
unlik
acyclovir
penciclovir
oblig
chain
termin
effect
inhibitor
dna
chain
elong
also
despit
less
power
inhibit
viral
dna
polymeras
acyclovir
famciclovir
much
higher
oral
bioavail
activ
form
phosphoryl
much
effici
significantli
longer
intracellular
halflif
herpesinfect
cell
may
ensur
prolong
antivir
activ
virusinfect
cell
may
respons
lower
conveni
dosag
regimen
famciclovir
resist
activ
metabolit
famciclovir
document
mechan
fulli
elucid
acyclovirresist
clinic
isol
hsv
vzv
defici
viral
thymidin
kinas
crossresist
pencicloirl
penciclovir
activ
vitro
howev
acyclovirresist
isol
hsv
vzv
alter
thymidin
kinas
dna
olymeras
foscarnetresist
hsv
isol
seem
suscept
penciclovir
r
ganciclovir
methyl
guanin
dhpg
cytoven
anoth
nucleosid
analog
guanin
antivir
activ
uniqu
howev
potent
acyclovir
cmv
although
vitro
activ
ganciclovir
equal
acyclovir
inhibit
hsv
vzv
toxic
lack
select
viral
enzym
limit
clinic
use
ganciclovir
treatment
prophylaxi
seriou
cmv
infect
immunocompromis
patient
ganciclovir
activ
monophosph
form
viralspecif
thymidin
kinas
hsvinfect
cell
cmvinfect
cell
phosphotransferas
encod
gene
cmv
convers
activ
triphosph
form
ganciclovir
accomplish
cellular
kinas
ganciclovir
triphosph
inhibit
viral
dna
synthesi
competit
inhibit
viral
dna
polymeras
direct
incorpor
viral
dna
therebi
termin
viral
dna
elong
mechan
resist
ganciclovir
cmv
includ
alter
gene
encod
viral
dna
mutat
catalyt
domain
phosphotransferas
gene
lead
defici
drug
phosphoryl
lol
cidofovir
l
phosphonylmethoxi
propyl
cytosin
hpmpc
novel
monophosph
nucleotid
analog
select
potent
inhibitor
cmv
replic
antivir
activ
herpesvirs
licens
unit
state
altern
ganciclovir
foscarnet
treatment
prophylaxi
cmv
retin
patient
aid
contain
phosphon
group
viralspecif
enzym
requir
initi
phosphoryl
unlik
ganciclovir
cidofovir
phosphoryl
cellular
enzym
activ
diphosph
form
select
inhibit
viral
dna
polymeras
may
prove
advantag
altern
treatment
herpesviru
resist
nucleosid
analog
caus
defici
alter
viral
enzym
requir
convers
certain
drug
monophosph
activ
diphosph
form
also
long
intracellular
halflif
allow
conveni
dosag
regimen
either
ganciclovir
foscarnet
ganciclovir
foscamet
must
administ
time
daili
initi
treatment
daili
mainten
wherea
cidofovir
given
weekli
week
follow
everi
week
vitro
combin
cidofovir
acyclovir
ganciclovir
foscamet
zidovudin
demonstr
addit
synergist
inhibit
sever
human
cmv
strain
although
viral
resist
cidofovir
demonstr
vitro
document
patient
treat
idoxuridin
iudr
trifluridin
trifluorothymidin
tft
viropt
two
thymidin
nucleosid
analog
use
topic
treatment
ocular
herp
simplex
viru
drug
repres
earliest
antivir
compound
develop
use
limit
toxic
insuffici
potenc
idoxuridin
trifluridin
phosphoryl
monophosph
form
viral
thymidin
kinas
hsvinfect
cell
triphosph
form
cellular
enzym
disrupt
viral
replic
thought
relat
inhibit
viral
dna
polymeras
exact
mechan
action
drug
unknown
current
trifluridin
licens
use
unit
state
activ
vaccinia
viru
strain
adenoviru
trifluridin
indic
topic
treatment
primari
keratoconjunct
recurr
epitheli
kerat
caus
use
topic
treatment
acyclovirresist
chronic
mucocutan
genit
hsv
infect
hivinfect
patient
viral
resist
idoxuridin
trifluridin
demonstr
vitro
resist
follow
clinic
use
report
resist
mutant
thought
possess
defici
alter
thymidin
kinas
activ
although
mutant
extens
isol
resist
idoxuridin
crossresist
trifluridin
foscamet
trisodium
phosphonoform
foscavir
unlik
describ
nucleosid
analog
use
herpesvirus
organ
analog
inorgan
pyrphosph
antivir
activ
cmv
vzv
ebv
hepat
b
viru
foscarnet
exert
inhibitori
effect
act
pyrophosph
bind
site
viralspecif
dna
polymeras
revers
transcriptas
phosphoryl
thymidin
kinas
kinas
requir
activ
foscarnet
thu
acyclovirresist
hsv
isol
tkor
tka
mutant
cmv
mutant
resist
ganciclovir
may
sensit
foscamet
resist
foscamet
caus
mutat
viral
dna
polymeras
acycloviror
ganciclovirresist
isol
alter
dna
polymeras
activ
may
resist
drug
foscarnet
indic
treatment
ganciclovirresist
cmv
retin
patient
treatment
acyclovirresist
mucocutan
hsv
infect
immunocompromis
acyclovirresist
vzv
also
success
treat
foscarnet
resist
clinic
hsv
isol
acyclovir
problem
grow
concern
occur
rate
immunocompromis
host
follow
prolong
cours
continu
intermitt
suppress
acyclovirresist
strain
hsv
recov
patient
aid
bone
marrow
solid
organ
transplant
recipi
patient
receiv
cancer
chemotherapi
children
agammaglobulinemia
sever
combin
immunodefici
neonat
laryng
herp
also
identifi
acyclovirresist
hsv
patient
resist
hsv
associ
chronic
progress
debilit
diseas
respond
antivir
treatment
resist
acyclovir
howev
usual
associ
sever
prolong
hsv
also
acyclovirresist
isol
may
becom
latent
caus
recurr
diseas
patient
recurr
caus
drugsensit
isol
success
treatment
infect
resist
v
rs
acyclovirresist
clinic
isol
hsv
tkmutant
although
tka
dna
polymeras
mutant
also
report
recoveri
acyclovirresist
clinic
isol
hsv
immunocompet
patient
acyclovirresist
hsv
isol
obtain
individu
therapybo
otherwis
healthi
patient
chronic
suppress
therapi
genit
although
longterm
treatment
seem
increas
risk
hsv
resist
correl
establish
isol
clinic
outcom
immunocompet
host
singl
report
suggest
recurr
acyclovirresist
hsv
infect
immunocompet
individu
correl
clinic
failur
antivir
viru
possess
tka
phenotyp
may
acquir
hivinfect
sexual
contact
receiv
longterm
acyclovir
therapi
recurr
genit
herp
foscarnet
employ
success
altern
antivir
agent
treat
tkor
tka
acyclovirresist
hsv
howev
vivo
resist
drug
also
doument
foscametresist
hsv
isol
show
absolut
borderlin
suscept
acyclovir
possibl
indic
acyclovir
foscarnet
possess
differ
bind
site
viral
dna
pl
e
r
e
highdos
oral
intraven
acyclovir
either
alon
combin
foscarnet
employ
success
treatment
foscarnetresist
hsv
altern
drug
famciclovir
valacyclovir
cidofovir
refer
trifluridin
also
may
consid
treatment
foscarnetresist
hsv
strain
bo
although
use
treat
isol
requir
investig
clinic
isol
resist
acyclovir
foscarnet
also
reprt
immunocompromis
patient
greater
risk
acquir
drugresist
hsv
strain
compar
host
normal
immun
still
unclear
suggest
increas
viral
burden
infect
immunocompromis
patient
favor
larger
gene
pool
emerg
viral
mutat
select
pressur
antivir
also
clinic
isol
hsv
may
repres
heterogen
popul
contain
suscept
resist
drugresist
strain
may
preferenti
select
antivir
therapi
acyclovir
prefer
drug
treatment
primari
vzv
infect
herp
zoster
immunocompromis
host
howev
acyclovirresist
clinic
isol
vzv
recov
adult
pediatr
aid
patient
present
indol
dissemin
atyp
hyperkeratot
nodular
lesion
follow
longterm
therapi
similar
acyclovirresist
hsv
isol
acyclovirresist
clinic
isol
vzv
defici
alter
thymidin
kinas
sever
vzv
isol
howev
report
resist
acyclovir
altern
drug
like
caus
mutat
viral
dna
polymeras
gene
may
also
result
combin
mutat
thymidin
kinas
dna
polymeras
gene
resist
cmv
ganciclovir
report
immunocompromis
patient
particularli
patient
aid
receiv
longterm
ganciclovir
treatment
cmv
retin
three
distinct
scenario
describ
develop
ganciclovirresist
cmv
patient
includ
infect
resist
viru
ganciclovir
treatment
infect
suscept
viru
becam
resist
cours
therapi
infect
initi
suscept
viru
emerg
genet
distinct
resist
viru
prevar
rate
report
ganciclovirresist
cmv
among
aid
patient
receiv
prolong
treatment
intraven
ganciclovir
cmv
retin
ganciclovirresist
clinic
isol
also
recov
bone
marrow
transplant
recipi
patient
chronic
lymphocyt
although
foscarnet
altern
therapi
ganciclovirresist
cmv
infect
clinic
cmv
isol
resist
foscamet
alon
combin
ganciclovir
resist
recent
doubl
resist
ganciclovir
foscamet
report
four
clinic
isol
cmv
obtain
four
differ
aid
patient
follow
multipl
sequenti
combin
cours
treatment
either
isol
repres
singl
cmv
strain
ganciclovir
resist
caus
mutat
phosphotransferas
gene
wherea
mutat
dna
polymeras
gene
respons
resist
fscarnet
number
antiretrovir
drug
approv
treatment
hiv
divid
three
main
class
base
mode
inhibit
viral
replic
tabl
first
class
repres
nucleosid
analog
inhibit
viral
rnadepend
dna
polymeras
revers
transcriptas
hiv
includ
drug
class
zidovudin
azt
retrovir
didanosin
ddi
videx
zalcitabin
dideoxycytidin
ddc
hivid
stavudin
zerit
lamivudin
epivir
second
class
revers
transcriptas
inhibitor
repres
nonnucleosid
analog
nevirapin
dipyridodiazepinon
viramun
delavirdin
bi
piperazin
rescriptor
third
class
proteas
inhibitor
includ
saquinavir
inviras
ritonavir
norvir
indinavir
crixivan
nelfinavir
viracept
therapi
antiretrovir
agent
either
alon
combin
may
benefici
prolong
surviv
reduc
incid
sever
opportunist
infect
patient
advanc
hiv
diseas
delay
diseas
progress
asymptomat
hivinfect
patient
nucleosid
analog
dideoxynucleosid
convert
cellular
enzym
mono
di
activ
triphosph
form
interact
substrat
bind
site
competit
inhibit
activ
viral
revers
triphosph
form
also
act
altern
substrat
incorpor
grow
dna
chain
lead
chain
termin
spectrum
activ
drug
extend
virus
depend
revers
transcriptas
similar
enzym
includ
hiv
retrovirus
hepat
b
viru
nonnucleosid
analog
target
enzym
nucleosid
analog
interact
enzym
differ
way
antivir
activ
requir
intracellular
convers
compound
interact
directli
revers
transcriptas
act
noncompetit
alloster
nonsubstr
bind
site
enzym
nonnucleosid
revers
transcriptas
inhibitor
highli
select
potent
inhibitor
replic
inact
retrovirus
equal
effect
aztsensit
aztresist
isol
similar
nucleosid
analog
also
excel
oral
bioavail
proteas
inhibitor
newli
develop
class
antiretrovir
drug
select
inhibit
viral
proteas
hiv
proteas
cleav
viral
gagpol
polyprotein
precursor
gag
protein
enzym
integras
proteas
viru
assembl
matur
enzym
requir
viral
infect
inhibit
h
n
proteas
activ
therefor
lead
develop
immatur
noninfecti
viral
particl
proteas
inhibitor
act
postintegr
step
hiv
replic
distinct
advantag
revers
transcriptas
inhibitor
block
late
stage
viral
replic
therebi
prevent
spread
hiv
cell
alreadi
infect
viru
major
disadvantag
proteas
inhibitor
low
solubl
aqueou
medium
poor
oral
bioavail
howev
oral
bioavail
solubl
certain
proteas
inhibitor
significantli
enhanc
appropri
chemic
modif
drug
develop
h
n
resist
variou
antiretrovir
drug
well
document
patient
receiv
antiretrovir
therapi
number
origin
articl
subject
extens
reader
refer
refer
comprehens
review
literatur
emerg
hiv
antivir
drug
resist
thought
function
length
therapi
stage
diseas
viral
burden
high
spontan
mutat
rate
viral
genom
activ
replic
viru
prolong
therapi
advanc
diseas
increas
likelihood
develop
viral
resist
vitro
vivo
resist
variou
antiretrovir
drug
caus
accumul
specif
mutat
code
region
either
revers
transcriptas
proteas
viru
lead
singl
amino
acid
substitut
viral
protein
target
extent
resist
seem
correl
number
mutat
although
individu
mutat
interact
caus
chang
resist
suscept
hiv
isol
longterm
monotherapi
nucleosid
analog
azt
ddi
ddc
led
recoveri
drugresist
hiv
isol
resist
seem
develop
within
month
initi
therapi
drug
mutat
revers
transcriptas
gene
codon
confer
resist
azt
individu
mutat
caus
lowlevel
resist
wherea
four
mutat
requir
highlevel
resist
azt
highlevel
azt
resist
develop
time
associ
rapid
clinic
progress
diseas
receiv
therapi
also
aztresist
viru
transmit
parenter
exposur
hninfect
blood
sexual
contact
mother
fetu
similarli
mutat
revers
transcriptas
gene
codon
associ
resist
ddi
crossresist
ddc
wherea
chang
codon
also
suppress
effect
azt
resist
mutat
codon
restor
sensit
isol
azt
resist
ddc
also
associ
mutat
codon
wherea
crossresist
ddi
observ
mutat
codon
addit
point
mutat
posit
associ
resist
posit
resist
select
pressur
azt
crossresist
antiretrovir
agent
uncommon
confin
nucleosid
analog
azido
group
therefor
aztresist
virus
remain
suscept
nucleosid
analog
nonnucleosid
analog
proteas
inhibitor
unlik
nucleosid
analog
resist
monotherapi
develop
within
day
week
high
level
resist
confer
singl
mutat
codon
mutat
codon
also
revers
effect
multipl
azt
resist
mutat
rapid
develop
resist
viru
also
observ
mani
patient
treat
nonnucleosid
resist
drug
occur
within
day
week
result
one
number
possibl
mutat
gene
revers
transcriptas
mutat
occur
around
site
nonnucleosid
analog
bind
case
nevirapin
cluster
codon
resist
one
nonnucleosid
analog
usual
confer
complet
crossresist
member
group
mutat
codon
caus
highlevel
nevirapin
resist
crossresist
nonnucleosid
revers
transcriptas
inhibitor
suppress
effect
azt
resist
mutat
coresist
azt
nevirapin
develop
mutat
codon
describ
resist
hiv
isol
delavirdin
also
confer
increas
suscept
isol
nonnucleosid
inhibitor
rapid
develop
viral
resist
nonnucleosid
analog
potenti
agent
monotherapi
limit
use
combin
antiretrovir
drug
human
immunodefici
viru
isol
resist
proteas
inhibitor
select
laboratori
passag
presenc
given
drug
viva
number
mutat
within
proteas
gene
recogn
confer
viral
resist
proteas
inhibitor
includ
codon
crossresist
multipl
proteas
inhibitor
follow
resist
singl
proteas
inhibitor
also
describ
monotherapi
avail
antiretrovir
agent
limit
success
prolong
treatment
hiv
infect
led
occurr
drugresist
virus
efficaci
combin
therapi
ultim
goal
combin
therapi
effect
inhibit
viral
replic
reduc
viral
burden
extrem
low
level
long
possibl
preserv
immun
function
prevent
develop
drug
resist
interrupt
progress
diseas
mind
certain
combin
drug
may
demonstr
addit
synergist
antivir
effect
alreadi
describ
ongo
studi
nucleosid
analog
nonnucleosid
analog
proteas
inhibitor
also
combin
select
antiretrovir
drug
act
differ
stage
viral
replic
induc
crossresist
creat
increas
toxic
may
benefici
adequ
manag
hiv
diseas
respiratori
virus
repres
heterogen
group
agent
infect
human
respiratori
tract
caus
signific
morbid
mortal
sever
ill
commonli
occur
infant
elderli
chronic
ill
immunocompromis
virus
major
caus
acut
respiratori
diseas
includ
influenza
b
virus
respiratori
syncyti
viru
parainfluenza
viru
type
adenovirus
rhinovirus
respiratori
coronavirus
treatment
infect
virus
howev
mostli
support
number
avail
antivir
drug
use
limit
oral
amantadin
rimantadin
employ
influenza
viral
ill
l
aerosol
ribavirin
use
rsv
infect
see
tabl
amantadin
hydrochlorid
symmetrel
alphamethyl
deriv
rimantadin
flumadin
primari
symmetr
amin
inhibitori
replic
influenza
viru
three
antigen
subtyp
isol
human
ie
neither
drug
suffici
activ
influenza
b
viru
isol
drug
licens
unit
state
treatment
prophylaxi
influenza
viru
rimantadin
fewer
side
effect
longer
halflif
easier
onceaday
use
administr
either
drug
within
hour
onset
ill
reduc
sever
durat
influenza
diseas
among
healthi
individu
mechan
action
ident
involv
interfer
function
transmembran
domain
viral
matrix
protein
therebi
inhibit
uncoat
viru
drug
also
shown
prevent
viru
assembl
later
stage
viral
replic
amantadineresist
rimantadineresist
influenza
isol
recov
adult
pediatr
patient
undergo
therapi
prophylaxi
epidem
influenza
diseas
resist
develop
rapidli
occur
within
day
start
treatment
viral
resist
caus
point
mutat
gene
encod
proteinlo
resist
isol
transmiss
close
contact
caus
typic
influenza
illn
crossresist
amantadin
rimantadin
report
complet
role
altern
antivir
compound
prevent
therapi
influenza
infect
fulli
defin
ribavirin
virazol
synthet
nucleosid
analog
resembl
guanosin
inosin
drug
broad
vitro
antivir
activ
mani
rna
dna
virus
includ
rsv
influenza
b
virus
parainfluenza
virus
adenovirus
herpesvirus
bunyavirus
arenavirus
reovirus
convert
cellular
enzym
mono
di
triphosph
form
monoand
triphosph
form
activ
although
exact
mechan
action
unknown
seem
interfer
express
viral
mrna
inhibit
viral
protein
synthesi
ribavirin
report
clinic
efficaci
rsv
influenza
b
hantaviru
lassa
fever
viru
infect
licens
unit
state
aerosol
treatment
hospit
infant
young
children
sever
lower
respiratori
tract
infect
caus
rsv
expens
mode
therapi
limit
use
antivir
drug
viral
resist
ribavirin
follow
patient
therapi
document
date
interferon
belong
class
immunomodul
call
cytokin
small
glycoprotein
peptid
function
like
hormon
regul
immun
system
also
releas
eukaryot
cell
respons
viral
infect
act
surround
uninfect
cell
render
resist
infect
variou
dna
rna
virusess
interferon
bind
specif
cellsurfac
receptor
intern
cell
induc
cellular
activ
prevent
viral
penetr
uncoat
synthesi
express
viral
mrna
viral
protein
synthesi
viral
assembl
releas
three
major
class
human
interferon
includ
interferona
interferon
interferon
interferona
approv
use
treatment
certain
viral
infect
tabl
chronic
liver
diseas
caus
hepat
b
c
virus
condyloma
acuminatum
caus
human
papillomavirus
shown
respond
treatment
interferona
also
interferona
antiretrovir
activ
replic
hiv
directli
inhibit
viru
assembl
releas
vivo
action
interferona
role
antivir
agent
virus
avoid
effect
drug
complex
yet
complet
understood
describ
emerg
antivir
drug
resist
led
definit
need
vitro
antivir
suscept
test
laboratori
confirm
drug
resist
may
predict
treatment
failur
defin
crossresist
antivir
agent
lead
institut
appropri
altern
therapi
clinic
situat
warrant
use
antivir
suscept
test
includ
failur
hsv
vzv
lesion
resolv
appear
new
lesion
acyclovir
therapi
progress
cmv
diseas
ganciclovir
therapi
continu
shed
transmiss
influenza
viru
treatment
prophylaxi
amantadin
rimantadin
progress
hiv
diseas
measur
increas
rna
plasma
level
decreas
cell
count
patient
antiretrovir
therapi
end
phenotyp
genotyp
antivir
suscept
assay
develop
determin
viral
drug
resist
number
phenotyp
assay
describ
test
suscept
virus
antivir
agent
gener
phenotyp
antivir
suscept
assay
requir
isol
passag
viru
cell
cultur
test
begin
standard
inoculum
viru
use
infect
cell
cultur
variou
concentr
antivir
agent
ad
activ
antivir
agent
replic
viru
measur
one
mani
method
includ
inhibit
plaqu
format
virusinduc
cytopath
effect
decreas
product
viral
antigen
enzym
activ
total
viru
yield
reduct
viral
nucleic
acid
synthesi
inhibit
cell
transform
method
result
express
drug
concentr
caus
inhibit
growth
viru
phenotyp
antivir
suscept
assay
develop
current
use
hsv
cmv
vzv
influenza
viru
assay
proven
accur
reliabl
determin
antivir
resist
import
caveat
phenotyp
antivir
suscept
test
howev
standard
exist
mani
variabl
influenc
final
result
comparison
vitro
suscept
data
among
differ
laboratori
valid
assay
host
cell
viru
inoculum
rang
drug
concentr
use
definit
sensit
resist
isol
may
differ
assay
system
differ
laboratori
perform
assay
effort
develop
standard
consensu
assay
hsv
cmv
current
progress
except
hsv
phenotyp
antivir
suscept
test
also
take
mani
week
complet
slowgrow
virus
cmv
vzv
therefor
may
rapid
enough
influenc
therapeut
decis
current
goal
virus
develop
rapid
phenotyp
assay
vitro
suscept
result
also
may
alway
correl
clinic
respons
hsv
isol
resist
acyclovir
vitro
respond
antivir
treatment
patient
isol
remain
suscept
acyclovir
vitro
fail
furthermor
patient
possess
heterogen
popul
viral
isol
differ
vitro
suscept
given
genotyp
assay
develop
rapid
detect
genet
mutat
confer
viral
drug
resist
assay
involv
use
polymeras
chain
reaction
pcr
amplif
specif
viral
gene
direct
sequenc
amplifi
product
identifi
alter
viral
genom
known
associ
viral
resist
given
antivir
agent
genotyp
assay
use
screen
cmv
isol
identif
mutat
cmv
phosphotransferas
gene
dna
polymeras
gene
confer
resist
ganciclovir
andor
fscarnet
loo
also
assay
employ
detect
specif
mutat
revers
transcriptas
proteas
gene
follow
treatment
patient
antiretrovir
sitedirect
mutagenesi
use
produc
new
recombin
viru
possess
defin
genet
mutat
demonstr
presenc
suspect
drugresist
mutat
caus
chang
drug
suscept
viru
genotyp
assay
offer
distinct
advantag
phenotyp
assay
speed
effici
analyz
larg
number
viral
isol
howev
assay
cumbersom
technic
demand
routin
avail
clinic
laboratori
also
current
genotyp
assay
detect
known
drugresist
mutat
result
may
confound
presenc
mutat
bear
drug
resist
phenotyp
assay
still
requir
identifi
drugresist
virus
novel
mutat
antivir
resist
develop
laboratori
assay
quantit
level
viru
infect
individu
may
prove
valuabl
laboratori
tool
assess
diseas
progress
monitor
impact
antivir
therapi
predict
treatment
failur
emerg
drugresist
virus
molecular
method
quantit
competit
pcr
revers
transcriptasepcr
nucleic
acid
sequencebas
amplif
branchedchain
technolog
commerci
avail
accur
quantit
viral
nucleic
acid
cmv
hepat
b
c
virusesl
test
may
influenc
choic
initi
therapi
tailor
treatment
regimen
reduc
risk
viral
mutat
subsequ
viral
resist
sustain
decreas
patient
viral
load
treatment
suggest
appropri
antivir
effect
wherea
return
viral
load
pretreat
level
indic
drug
failur
possibl
need
altern
therapi
emerg
virus
resist
antivir
drug
grow
clinic
concern
failur
patient
respond
appropri
therapi
close
relat
develop
viral
resist
transmiss
drugresist
virus
patient
patient
document
although
great
advanc
made
product
new
effect
antivir
agent
virus
resist
singl
multipl
drug
continu
appear
select
pressur
prolong
treatment
viral
infect
immunocompromis
host
critic
understand
antivir
resist
appropri
therapeut
manag
patient
appreci
clinician
laboratori
personnel
magnitud
signific
problem
need
identifi
drugresist
viral
isol
defin
mechan
antivir
resist
inform
prove
invalu
prudent
select
administr
antivir
agent
